{"filing":{"accession_number":"0001104659-26-096483","cik":"0001737953","ticker":"REPL","company_name":"Replimune Group, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2623208d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_8k.htm"},"events":[{"id":27754,"run_id":25328,"accession_number":"0001104659-26-096483","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The company announced financial results for the fiscal first quarter ended June 30, 2026, including R\u0026D expenses ($49.3M), SG\u0026A expenses ($19.0M), and net loss ($69.8M), along with balance sheet data and cash position. The news release is furnished as Exhibit 99.1 and includes material corporate updates (FDA approval of TUDRIQEV, executive appointment, financing completion). This is material to investors as it provides quarterly financial performance and significant operational milestones.","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29419,"accession_number":"0001104659-26-096483","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company announced financial results for the fiscal first quarter ended June 30, 2026, including R\u0026D expenses ($49.3M), SG\u0026A expenses ($19.0M), and net loss ($69.8M), along with balance sheet data and cash position. The news release is furnished as Exhibit 99.1 and includes material corporate updates (FDA approval of TUDRIQEV, executive appointment, financing completion). This is material to investors as it provides quarterly financial performance and significant operational milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:11:43.416439+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29419,"accession_number":"0001104659-26-096483","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The company announced financial results for the fiscal first quarter ended June 30, 2026, including R\u0026D expenses ($49.3M), SG\u0026A expenses ($19.0M), and net loss ($69.8M), along with balance sheet data and cash position. The news release is furnished as Exhibit 99.1 and includes material corporate updates (FDA approval of TUDRIQEV, executive appointment, financing completion). This is material to investors as it provides quarterly financial performance and significant operational milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:11:43.416439+00:00","company_name":"Replimune Group, Inc.","ticker":"REPL","filing_date":"2026-08-14"}]}